Monday, October 3, 2022


Biotechnology News Magazine

Kymera Therapeutics Strengthens Leadership

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

February 3, 2021

Kymera Therapeutics, Inc., a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Ashwin Gollerkeri, MD, as Senior Vice President, Head of Development, and Kevin Dushney, as Vice President, Information Technology, as well as the promotion of Karen Martin, JD, Ph.D. to Vice President, Head of Legal.

“We continue to grow and broaden our organizational capabilities as we evolve toward becoming a fully integrated degrader medicines company,” said Nello Mainolfi, Ph.D., Co-Founder, President and CEO, Kymera Therapeutics. “In 2021, we expect to make significant strides in this mission with three novel protein degrader programs planned to enter clinical development across healthy volunteers, immune-inflammatory diseases, and cancer patients. We expect to benefit considerably from Ashwin’s expertise and track record in leading the development and approval of novel targeted oncology medicines. Further, Kevin and Karen will be important leaders in critical functions that will help guide Kymera Therapeutics toward becoming a fully integrated degrader medicine company.”

Ashwin Gollerkeri, MD, Senior Vice President, Head of Development: Dr. Gollerkeri joins Kymera Therapeutics with 20 years of drug development experience, including service at Pfizer Inc., Array BioPharma, Novartis AG, and Bristol-Myers Squibb Company (BMS). As Vice President of Clinical Science-Oncology at Array, Dr. Gollerkeri’s efforts led to successful filings of New Drug Applications for the targeted cancer therapies BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib).

He has also held various leadership roles in clinical development and research at Pfizer, Novartis, and BMS. He holds a BA degree in Cell and Developmental Biology from Northwestern University and an MD from the University of Kansas School of Medicine. He subsequently trained in Internal Medicine and completed a Chief Residency at The Miriam Hospital-Brown University School of Medicine and in Medical Oncology at Yale University School of Medicine.

Kevin Dushney, Vice President, Information Technology: Mr. Dushney joins Kymera with over 20 years of experience in information technology (IT) in the biopharmaceutical industry, including extensive experience in planning, designing, and implementing innovative IT strategies and solutions to support growth across preclinical to commercial-stage organizations. He previously held IT and operations leadership roles at Editas Medicine, Inc., Synageva Biopharma Corp., Zafgen, Inc., Alnylam Pharmaceuticals, and others. Mr. Dushney received a BA degree from the University of Massachusetts Amherst.

Karen Martin, JD, PhD, Vice President, Head of Legal: Dr. Martin joined Kymera in April 2020 as Vice President, Head of Intellectual Property, with over 16 years of legal experience in the biotechnology and pharmaceutical industries.

Prior to Kymera Therapeutics, she was Lead IP Counsel, US Business Unit at Takeda Pharmaceuticals (formerly Shire PLC), where she developed patent and trademark portfolios for assets in oncology, ophthalmology, and rare diseases. She previously practiced intellectual property law at Wolf Greenfield & Sacks. Dr. Martin obtained her law degree from Suffolk University Law School and holds a PhD in Organic Chemistry from the Massachusetts Institute of Technology and a BS in Chemistry from Boston College.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine